Comparative Pharmacology
Head-to-head clinical analysis: FLUMADINE versus TPOXX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUMADINE versus TPOXX.
FLUMADINE vs TPOXX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rimantadine inhibits the replication of influenza A virus by blocking the M2 ion channel, thereby preventing viral uncoating and the release of viral RNA into host cells. It also has weak NMDA receptor antagonist properties.
TPOXX (tecovirimat) inhibits the orthopoxvirus VP37 envelope protein, preventing viral egress from infected cells and reducing viral spread.
100 mg orally twice daily for 7-10 days; initiate within 48 hours of symptom onset.
600 mg orally twice daily for 14 days.
None Documented
None Documented
Terminal elimination half-life: 16-48 hours (mean ~24 hours). In elderly (>70 years) or severe renal impairment (CrCl <10 mL/min), half-life may exceed 100 hours, requiring dose reduction.
Terminal half-life ~19 hours (range 10–48 h) in healthy adults; prolonged in renal impairment (up to ~100 h).
Renal: 85% unchanged via glomerular filtration and tubular secretion; Fecal: <5%
Fecal (primarily as unchanged drug, ~75%); renal (~25%, mostly as metabolites; <2% unchanged in urine).
Category C
Category C
Antiviral Agent
Antiviral Agent